Toschnerová H, Ceska R, Sobra J, Traurig J
II. interní klinika 1. LF UK, Praha.
Cas Lek Cesk. 1993 May 18;132(10):308-10.
Duolip forte (ethophylline clofibrate, tablets à 500 mg) produced by Merckle Austria was administered to 20 patients with different types of hyperlipoproteinaemia for a 6-month period in amounts of 500 mg/day. Before onset of treatment and during treatment the patients adhered to a defined hypolipidaemic diet. The total cholesterol level during administration increased from 7.71 +/- 1.71 mmol/l to 8.23 +/- 1.34 mmol/l (p = 0.05). The LDL cholesterol level rose from 4.93 +/- 1.70 mmol/l to 5.53 +/- 1.34 mmol/l (n.s.). Apolipoprotein B declined from 1.99 +/- 0.39 g/l to 1.80 +/- 0.30 g/l (n.s.). HDL cholesterol rose from 1.09 +/- 0.32 mmol/l to 1.53 +/- 0.56 mmol/l (p = 0.01). The triglyceride level declined from 5.71 +/- 5.60 mmol/1 to 3.72 +/- 4.32 mmol/1 (n.s.). The lipid metabolism parameters were evaluated already after three months of Duolip treatment but the values did not differ significantly from values assessed after 6 months of administration; therefore only the final values are given. In the course of six months of Duolip administration the body weight of the patients did not change and no serious side-effects were observed which would call for discontinuation of treatment. Duolip forte is evaluated as a safe, but as compared with other available drugs of the clofibrate series, less effective hypolipidaemic agent.
奥地利默克公司生产的多利平酯（益多酯，500毫克片剂），以每日500毫克的剂量给予20名不同类型高脂蛋白血症患者，为期6个月。在治疗开始前及治疗期间，患者遵循特定的降血脂饮食。给药期间，总胆固醇水平从7.71±1.71毫摩尔/升升至8.23±1.34毫摩尔/升（p = 0.05）。低密度脂蛋白胆固醇水平从4.93±1.70毫摩尔/升升至5.53±1.34毫摩尔/升（无统计学意义）。载脂蛋白B从1.99±0.39克/升降至1.80±0.30克/升（无统计学意义）。高密度脂蛋白胆固醇从1.09±0.32毫摩尔/升升至1.53±0.56毫摩尔/升（p = 0.01）。甘油三酯水平从5.71±5.60毫摩尔/升降至3.72±4.32毫摩尔/升（无统计学意义）。在多利平治疗三个月后就对脂质代谢参数进行了评估，但这些值与给药6个月后评估的值没有显著差异；因此只给出了最终值。在多利平给药的六个月期间，患者体重没有变化，也未观察到需要停药的严重副作用。多利平酯被评估为一种安全的降血脂药物，但与氯贝丁酯系列的其他现有药物相比，效果较差。
